TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS

New PDUFA goal date of December 28, 2022 NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has extended...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news